Nomination Committee appointed for Dicot Pharma AB

In accordance with the instruction for the Nomination Committee adopted by the Annual General Meeting, the members of Dicot Pharma's Nomination Committee shall be appointed by the three largest shareholders/owner groups in the company as of September 31, 2024, who wish to appoint a member.

The Nomination Committee has now been appointed and consists of the following three members:

• Göran Beijer, appointed by Bertil Lindkvist
• Tore Robertsson, representing Tor Finans AB
• Torsten Söderberg, representing Syoto AB and own holding

Försäkringsaktiebolaget Avanza Pension and Nordnet Pensionsförsäkring AB have both declined to appoint representatives.

Tore Robertsson has been appointed Chairman of the Nomination Committee and has asked the Chairman of the Board, Eva Sjökvist Saers, to act as convener. No fees shall be paid to the members of the Nomination Committee.

The Nomination Committee is responsible for preparing and presenting proposals for the Chairman of the Board, Board members, Board fees (divided between the Chairman, Board members and any committees), the Chairman of the AGM, auditors' fees and the election of auditors. The Nomination Committee's proposals are submitted in connection with the notice of the next Annual General Meeting.

Shareholders who wish to submit proposals to the Nomination Committee can do so by e-mail to [email protected]. For the Nomination Committee to be able to process proposals received in a constructive manner, these should be received by the Nomination Committee no later than December 20, 2024.

Dicot Pharma's Annual General Meeting 2025 will be held on Tuesday, May 6, 2025, at 17.00 in Uppsala.

For further information, please contact:

Eva Sjökvist Saers, chairman of the board
Phone: +46 70 550 7371
E-mail: [email protected]

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 7,200 shareholders. For more information, please visit www.dicotpharma.com.